CIK 0000872912 · Non-accelerated filer<br>Smaller reporting company
DELCATH SYSTEMS, INC.
Sign in to watch- Ticker
- DCTH
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 061245881
- Phone
- (518) 743-8892
- Business address
- 566 QUEENSBURY AVENUE, QUEENSBURY, NY, 12804
- Former names
- DELCATH SYSTEMS, INC., DELCATH SYSTEMS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $488,508
- in 1 filing
Net −$488,508. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-12 | Martell Bridget A Director | Option exercise | +22,500 | $7.85 | $177K | 22,500 |
| 2026-11-12 | Martell Bridget A Director | Sale | −20,570 | $21.66 | $446K | 1,930 |
| 2026-11-12 | Martell Bridget A Director | Sale | −1,930 | $22.26 | $43K | 0 |
| 2026-11-12 | Martell Bridget A Director | Option exercise · Stock Option (right to buy) | −22,500 | 0 | ||
| 2026-10-13 | Rosalind Advisors, Inc. Director | Conversion | +3,627 | 3,417,095 | ||
| 2026-10-13 | Rosalind Advisors, Inc. Director | Other disposition | −27,502 | 3,389,593 | ||
| 2026-10-13 | Rosalind Advisors, Inc. Director | Conversion · Series E preferred | −36.27 | 9,112.38 | ||
| 2026-05-13 | Aharon Gil Director | Grant or award · Stock Option (right to buy) | +22,500 | 22,500 | ||
| 2026-05-13 | Sylvester John Richard Director | Grant or award · Stock Option (right to buy) | +22,500 | 22,500 | ||
| 2026-05-13 | Martell Bridget A Director | Grant or award · Stock Option (right to buy) | +22,500 | 22,500 | ||
| 2026-05-13 | SALAMON STEVEN A J Director | Grant or award · Stock Option (right to buy) | +22,500 | 22,500 | ||
| 2026-05-13 | CZEREPAK ELIZABETH Director | Grant or award · Stock Option (right to buy) | +22,500 | 22,500 | ||
| 2026-03-06 | Pennell Sandra Chief Financial Officer | Purchase | +5,533 | $9.04 | $50K | 77,018 |
| 2026-03-02 | MICHEL GERARD J CHIEF EXECUTIVE OFFICER | Purchase | +11,200 | $8.96 | $100K | 342,034 |
| 2026-02-17 | Rook Martha S. CHIEF OPERATING OFFICER | Grant or award · Stock Option (Right to Buy) | +56,500 | 56,500 | ||
| 2026-02-17 | Rook Martha S. CHIEF OPERATING OFFICER | Grant or award · Restricted Stock Units | +28,250 | 28,250 | ||
| 2026-02-17 | Hoffman David L. GEN'L COUNSEL, CCO & SECY | Grant or award · Stock Option (Right to Buy) | +56,500 | 56,500 | ||
| 2026-02-17 | Hoffman David L. GEN'L COUNSEL, CCO & SECY | Grant or award · Restricted Stock Units | +28,250 | 28,250 | ||
| 2026-02-17 | Muir Kevin GM INTERVENTIONAL ONCOLOGY | Grant or award · Stock Option (Right to Buy) | +56,500 | 56,500 | ||
| 2026-02-17 | Muir Kevin GM INTERVENTIONAL ONCOLOGY | Grant or award · Restricted Stock Units | +28,250 | 28,250 |
Page 1 of 7 · 138 trades